ROWATINEX 24,8 mg/1 kapsula+ 6,2 mg/1 kapsula+ < 15 mg/1 kapsula+ 3 mg/1 kapsula+ 4 mg/1 kapsula+ 10 mg/1 kapsula+ 4 mg/1 kap Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

rowatinex 24,8 mg/1 kapsula+ 6,2 mg/1 kapsula+ < 15 mg/1 kapsula+ 3 mg/1 kapsula+ 4 mg/1 kapsula+ 10 mg/1 kapsula+ 4 mg/1 kap

medical intertrade d.o.o. sarajevo - alfa-pinen, anetol, beta-pinen, борнеол, cineol, fenhon, kamfen - želučanootporna kapsula, meka - 24,8 mg/1 kapsula+ 6,2 mg/1 kapsula+ < 15 mg/1 kapsula+ 3 mg/1 kapsula+ 4 mg/1 kapsula+ 10 mg/1 kapsula+ 4 mg/1 kapsula - 1 želučanootporna kapsula, meka sadrži: 24,8 mg alfa pinen, 6,2 mg beta pinen, 15 mg kamfen, 3 mg cineol, 4 mg fenhon, 10 mg borneol, 4 mg anetol

Prepandrix Europska Unija - hrvatski - EMA (European Medicines Agency)

prepandrix

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) kao soj koji se koristio (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. ovaj prikaz se temelji na imunogenosti podataka od zdravih ispitanika u dobi od 18 i dalje godina nakon uvođenja dvije doze cjepiva, kuhani s podtipa h5n1 sojeva . prepandrix mora se koristiti u skladu sa službenim vodstvom.

HLA-Ready Plate ABC Complement Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

hla-ready plate abc complement

jasika d.o.o. za trgovinu i zastupanje remetinačka cesta 115 10000 zagreb -

Diamox 250 mg tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

diamox 250 mg tablete

amdipharm limited, 3 burlington road, dublin, irska - acetazolamid - tableta - 250 mg - urbroj: jedna tableta sadrži 250 mg acetazolamida

TRIUMEQ 50 mg/1 tableta+ 600 mg/1 tableta+ 300 mg/1 tableta filmom obložena tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

triumeq 50 mg/1 tableta+ 600 mg/1 tableta+ 300 mg/1 tableta filmom obložena tableta

evropa lijek pharma d.o.o. - абакавир, долутегравир, lamivudin - filmom obložena tableta - 50 mg/1 tableta+ 600 mg/1 tableta+ 300 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg dolutegravira (u obliku dolutegravirnatrija) 600 mg abakavira (u obliku abakavirsulfata) 300 mg lamivudina

Jyseleca Europska Unija - hrvatski - EMA (European Medicines Agency)

jyseleca

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Rinvoq Europska Unija - hrvatski - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.